Effects of interleukin (IL)-17A and @entity4654 in human XXXX synoviocytes.

@entity39 @entity5 @entity16 @entity4155 @entity4654 @entity309
@entity309 ( @entity309 ) is a chronic inflammatory disease where the contribution of T cells is now supported by clinical results. Among the cytokines produced by T cells, interleukin (IL)-17A (previously known as @entity4155 ) and @entity4654 constitute the signature cytokines of the newly described Th17 T helper cell subset. While the effects of @entity4155 on @entity309 synoviocytes been well described, those of @entity4654 remain less studied. The present review describes the effects of @entity4155 and @entity4654 on synoviocytes and their contribution to @entity309 pathogenesis. Although @entity4654 is less active than @entity4155 when used alone, @entity4155 and @entity4654 induce in synoviocytes a rather similar expression pattern in the presence of @entity5 @entity39 factor a. They enhance their response by stabilising mRNA of cytokines and enhancing receptor expression. They increase the migration, chemokine gene expression and invasiveness of synoviocytes. They contribute to disease chronicity by inhibiting synoviocyte apoptosis. Finally, they enhance metalloprotease secretion leading to @entity16 . These properties support the combined inhibition of @entity4155 and -F to control @entity309 and joint destruction.
